SCHIZOPHRENIA AND RELATED DISORDERS: Edited by Lynn E. DeLisi and Iris E.C. SommerDo we need sex-oriented clinical practice guidelines for the treatment of schizophrenia?Fernando, Piyumia; Sommer, Iris E.C.b; Hasan, Alkomieta,cAuthor Information aDepartment of Psychiatry and Psychotherapy, University Hospital München, Ludwig-Maximilians University München, Germany bDepartment of Biomedical Science of Cells and Systems, and Department of Psychiatry (UCP), Rijks Universiteit Groningen (RUG), Universitair Medisch Centrum Groningen (UMCG), Groningen, The Netherlands cDepartment of Psychiatry, Psychotherapy and Psychosomatics of the University Augsburg, Bezirkskrankenhaus Augsburg, University of Augsburg, Augsburg, Germany Correspondence to Alkomiet Hasan, MD, Department of Psychiatry and Psychotherapy, Klinikum der Universität München, Ludwig-Maximilians University Munich, Nußbaumstraße 7, D-80336 Munich, Germany. Tel: +49 4400 55505; fax: +49 4400-55530; e-mail: email@example.com Current Opinion in Psychiatry: May 2020 - Volume 33 - Issue 3 - p 192-199 doi: 10.1097/YCO.0000000000000597 Buy Metrics Abstract Purpose of review Clinical practice guidelines (CPGs) do not usually offer a sex-specific approach for the management of schizophrenia. With this narrative review, we aim to give an integrated and synthesized overview of the current state of knowledge regarding sex-specific aspects in schizophrenia and how this topic may be adapted in the development of CPGs. Recent findings Recent studies further suggest sex-specific differences in epidemiologic features, the course of illness, underlying pathomechanisms, response likelihood to antipsychotic medication and differences in tolerability. Beyond this, selective estrogen receptor modulators like raloxifene have shown beneficial effects on symptom severity and cognition in women with schizophrenia. Summary Sex-specific aspects can already be integrated in clinical guideline recommendations, especially with regard to efficacy and tolerability of antipsychotic treatment. Moreover, these aspects may be used for an individual risk-stratification. Recent studies provide evidence supporting the hypothesis of sex-specific modulation in schizophrenia and build the groundwork for sex-specific novel treatment options. However, there remains a clear need for additional studies focusing on women with schizophrenia to substantiate current findings. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.